STAR: A Phase 2, Multicenter, Randomized, Double Masked, Placebo Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia
Principal Investigator
Kevin Gregory-EvansOverview
Body Locations and Systems
Eye DisordersClinicalTrials.gov#
NCT02647359Status
Closed for RecruitmentStudy Start/End
Jan 21, 2016 to Jan 31, 2018Locations
Vancouver General HospitalName/Title
Cheryl Gregory-Evans, ProfessorPhone
604-875-5529Email Address
cge30@mail.ubc.caPurpose of Study
This is a Phase 2, randomized, double-masked, placebo-controlled study of ataluren in patients with aniridia caused by a nonsense mutation. Patients will receive masked study drug for 48 weeks followed by open-label ataluren for another 48 weeks. Safety and efficacy will be assessed.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.